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Current treatments of many advanced malignancies,
including melanoma, have failed to significantly
reduce mortality rates, necessitating newer ap-
proaches. There is now abundant evidence that
cancer cells, given the appropriate environmental
and molecular context, are capable of remarkable
plasticity, including complete reversal of the malig-
nant phenotype. Such reprogramming involves both
extrinsic and intrinsic factors and can occur via three
routes: perturbations of extracellular matrix–cell
receptor interactions, modulation of intracellular
signaling pathways, and exploitation of epigenetic
inheritance. Studies demonstrate the potential for
producing dramatic changes in structural, biochemical,
immunological, and functional properties of a broad
spectrum of tumor cell types, including melanoma,
leading to growth arrest, differentiation, senescence,
or self destruction. Translating the promise inherent
in tumor cell plasticity to the clinical arena remains a
major challenge, but it is likely that a variety of
epigenetic methods will play an increasingly impor-
tant and effective role in the future control of
malignant melanoma and other cancers.
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INTRODUCTION
Because current treatments for many advanced disseminated
malignancies, including melanoma, have failed to signifi-
cantly reduce mortality rates, increasing attention is now
being directed at alternative, biologically rooted, epigenetic
approaches (Jones and Laird, 1999). Epigenetics refers to the
stable transmission of heritable information by means that do
not involve changes in the DNA sequence. While it is
well established that tumor initiation and progression
involve stepwise accumulation of multiple genetic changes
(Vogelstein et al., 1988), there is also abundant evidence that
even in the presence of irreversible genetic alterations a
variety of epigenetic influences can bring about selective
changes in gene expression leading to remarkable plasticity
(the ability of tumor cells to express the characteristics of
multiple different types of cells). Such reprogramming, by
normalizing tissue and cellular architecture and their links to
cell signaling, can produce dramatic shifts in structural,
biochemical, immunological, and functional properties of
cancer cells, including temporary or permanent reversal of
malignancy.
EXTRINSIC INFLUENCES ON TUMOR CELL PLASTICITY:
ECM–CELL RECEPTOR INTERACTIONS
These epigenetic influences may be either extrinsic or
intrinsic to the cancer cell. Most important among the
extrinsic (extracellular) factors controlling phenotypic expres-
sion are those involving interactions between cell receptors
and the extracellular matrix (ECM). Normal stromal fibro-
blasts can, under certain experimental conditions, impose
severe constraints on proliferation, differentiation, and
metastasis of malignant cells (Moinfar et al., 2000), whereas
in contrast, fibroblasts activated by cancer cells, growth
factors, chemical carcinogens, or low-dose ionizing radiation
(Atula et al., 1997; Barcellos-Hoff and Ravani, 2000; Tlsty
and Hein, 2001; Tsai et al., 2005), as well as by senescent
fibroblasts (Krtolica et al., 2001), can, by means of trophic
factors and matrix-remodeling enzymes, which perturb the
stromal microenvironment, stimulate growth of cancer cells.
It has been shown that the ECM, growth factors, and
hormones all play an important role in directing gene
expression by interacting with membrane-associated adhe-
sion molecules to affect actin and intermediate filament
complexes, as well as kinase- and phosphatase-directed
signaling pathways, which determine cellular phenotypes.
Perturbations in ECM–cell interactions are a constant feature
of many tumors, and genetic changes in stromal cells may
even, in some cases, precede genotypic changes in epithelial
cells (Moinfar et al., 2000).
One of the most thoroughly studied tumors is mammary
carcinoma, which arises from mammary epithelial cells,
where ECM, most critically the laminin 1 component of
basement membrane, has been shown to direct morphogen-
esis, tissue-specific gene expression, functional differentia-
tion, and nuclear organization (Lelie`vre et al., 1998;
Kenny and Bissell, 2003). In a human breast tumor-
progression model, treatment of tumor cells in a three-
dimensional laminin-rich basement membrane (Matrigel)
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with an inhibitory function-blocking b-1-integrin antibody or
its Fab fragment induced reversion to a normal phenotype,
with reestablishment of normal morphology, including
cytoskeletal rearrangements of actin and cytokeratin 18
intermediate filament networks, organization of adherens
junctions, and reestablishment of E-cadherin–b-catenin com-
plexes (Weaver et al., 1997). These changes accompanied
growth arrest with decreased cyclin D-1 levels and exit from
the cell cycle. Thus, a normal phenotype was restored by
introducing a specific structural cue involved in ECM–cell
interactions. The reverted cells produced significantly fewer
tumors in vivo. In the absence of the inhibitory antibody, cells
reverted to the malignant state, emphasizing the bidirectional
nature of plasticity. In other studies, it was shown that
b-4-integrin is required for maintenance of a normal
phenotype, but can, when overexpressed, function as a
signaling accomplice of tyrosine kinase proto-oncogenes in
carcinogenesis (Berlotti et al., 2005).
In addition to integrins, other molecules, which are
required for normal differentiation of prostate and mammary
epithelial cells, include the basement membrane receptor
dystroglycan, and the carcinoembryonic antigen-related cell
adhesion molecule 1 (Henry et al., 2001; Muschler et al.,
2002; Kirshner et al., 2003). Overexpression of either
carcinoembryonic antigen-related cell adhesion molecule 1
or dystroglycan in breast cancer cells resulted in morphologic
reversion, and in the case of dystroglycan, blocked tumor-
igenesis (Muschler et al., 2002; Kirshner et al., 2003), whereas
carcinoembryonic antigen-related cell adhesion molecule 1
suppressed both prostate and hepatic tumorigenesis (Estrera
et al., 1999; Laurie et al., 2005). Thus, appropriate modifica-
tion of transmembrane signaling receptors can restore normal
form and function, reducing tumorigenicity.
It was shown quite early that in general the malignant
phenotype could be suppressed by a normal extracellular
environment. Thus, embryonal carcinoma cells placed in
blastocysts formed a variety of normal structures (Kleinsmith
and Pierce, 1964; Mintz and Illmensee, 1975), whereas Rous
sarcoma virus failed to induce malignant transformation in
chickens in the absence of wounding sufficient to disturb
tissue structure at local injection sites (Dolberg et al., 1985;
Boudreau et al., 1995). Reversion of the malignant phenotype
by normal ECM was also effected when basal cell carcinoma
cells were transplanted to an intrauterine location (Cooper
and Pinkus, 1997), when rat prostatic adenocarcinoma cells
were embedded in normal seminal vesicle mesenchyme
(Hayashi and Cunha, 1991), and when human colon
carcinoma cells were grown in organ culture with fetal rat
mesenchyme (Fukamachi et al., 1986). It is important to note
that at present no common mechanism has been determined
to explain the phenotypic reversion observed with these
diverse tumor types.
INTRINSIC INFLUENCES ON TUMOR CELL PLASTICITY:
SIGNALING PATHWAYS AND EPIGENETIC
INHERITANCE
Among the intrinsic epigenetic factors affecting the malignant
phenotype are signaling pathways and their receptors,
various oncogenes, and epigenetic inheritance. Correcting
abnormal signaling pathways can induce either phenotypic
reversion or cell death (Wang et al., 2002). Thus, for
example, in tumors overexpressing the epidermal growth
factor receptor, inhibiting either the receptor or the activation
of its downstream signaling via mitogen-activated protein
kinase kinase and phosphatidyl inositol 3 kinase induced
phenotypic reversion (Kenny and Bissell, 2003). Oncogenes
required for maintenance of the malignant phenotype in
specific tumors include cMYC, RAS, Her-2/Neu allele, and
the BCL-Abl fusion gene; switching off these oncogenes can
lead to emergence of the normal phenotype, with sustained
tumor regression or even permanent loss of malignancy
(Huettner et al., 2000; Fisher et al., 2001; Jain et al., 2002;
Moody et al., 2002).
Also, and increasingly important with respect to potential
control of malignancy, are the complex independently
heritable epigenetic controls imposed upon gene expression
by covalent modification of DNA as well as by post-
translational modifications of histones which package that
DNA (for a review see Feinberg and Tycko, 2004). These
epigenetic controls include both hypo- and hypermethylation
of DNA, and methylation and acetylation/deacetylation of
histones. Each plays a critical role in transcriptional silencing
or activation of genes, with methylation of DNA acting on
CpG dinucleotides in promoter regions, and methylation and
acetylation of histones effecting changes in chromatin
conformation. The DNA and histone modifications interact
to ultimately determine gene expression (Jones et al., 1998;
Cameron et al., 1999), and agents that modulate both have
already been employed in clinical trials (Marks et al., 2000;
Karpf and Jones, 2002; Kelly et al., 2002; Sandor et al., 2002;
Dowell and Minna, 2004; Medrano, 2005). Interestingly, the
malignancy metastasis-associated synuclein-g gene is regu-
lated epigenetically (Liu et al., 2005).
Another fertile area of current investigation involves the
role of specific transcription factors in cancer cell survival,
proliferation, differentiation, and senescence, and the poten-
tial application of that information to therapy (Yamamoto and
Gaynor, 2001; Goding, 2005; Tanaka et al., 2006).
MELANOMA CELL PLASTICITY
Does the melanoma malignant phenotype also exhibit
plasticity, and is it subject to modulation? Several lines of
evidence provide an affirmative answer. The most striking is
the finding of a subpopulation of melanoma cells with the
properties of stem cells, capable of self-renewal and of
differentiation into multiple cell lineages, including melano-
cytic, adipocytic, osteocytic, and chondrocytic cell types
(Fang et al., 2005). Another example is the ability of
aggressive melanoma-derived cells to adopt endothelial-like
properties and mimic embryonic vasculogenic networks,
conferring in this case a poor clinical prognosis (Hendrix
et al., 2003). Formation of these vascular networks is
associated with appearance of the adhesive protein VE-
cadherin (CD 144), the receptor protein kinase Eph A2, and a
major component of basement membrane, laminin. All three
molecules are overexpressed in aggressive melanomas, and
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their downregulation completely abrogated vasculogenic
mimicry (Hendrix et al., 2003).
Additional evidence of melanocytic lineage plasticity is
the observation that normal melanocytes placed in an
inductive metastatic melanoma matrix underwent a reversi-
ble trans-differentiation of phenotype to that of aggressive
melanoma-like cells, with marked invasive and migratory
properties in the absence of significant genomic changes
(Seftor et al., 2005). In contrast, human metastatic melanoma
cells placed in a chick embryo microenvironment assumed a
neural crest-like phenotype (Kulesa et al., 2006), whereas
those transplanted to zebrafish embryos lost their tumori-
genicity (Lee et al., 2005). Furthermore in melanoma cells,
which have undergone the switch in cell-surface adhesion
molecules from E-cadherin to N-cadherin, a change that
favors increased survival, migration, and proliferation, re-
expression of E-cadherin reverses malignancy by restoring
keratinocyte-mediated growth control (Hsu et al., 2000;
Li et al., 2004). In another study, treatment of melanoma cells
with a combination of fibroblast IFN-b and mezerein induced
an irreversible loss of proliferative potential and multiple
changes toward a more benign phenotype (Fisher et al.,
1985). Other potential targets for reversing the melanoma
malignant phenotype include such downstream signaling
molecules as focal adhesion kinase and phosphatidyl inositol
3 kinase, and the small GTPases, Rac1 and Cdc42 (Hendrix
et al., 2003).
The earliest evidence that the melanoma malignant
phenotype is reversible epigenetically was the finding that a
‘‘contact-inhibitory factor’’ present in culture medium of a
revertant line of melanoma cells could restore in vitro growth
control (contact-, serum-, and anchorage-dependent growth)
to melanoma cells (Lipkin and Knecht, 1974; Lipkin et al.,
1986), cause early G1 growth arrest (Lipkin and Knecht,
1976), reorganize the actin cytoskeleton (Higgins et al.,
1988), induce synthesis of pigment differentiation antigens
(Lipkin et al., 1985), and upregulate class I major histocom-
patibility antigens (Lipkin and Meruelo, 1992), increasing
lysis by cytotoxic (CD8) T lymphocytes (unpublished data). It
also suppressed both angiogenesis (Lipkin et al., 2001) and
metastasis (unpublished data), and led to permanent regres-
sion of tumors treated in situ(Lipkin et al., 1989). The contact-
inhibitory factor was recently found to inhibit a key signaling
pathway (mammalian target of rapamycin (mTOR)) that
controls cell growth and proliferation, which may account
for its pleiotrophic affects (unpublished data).
MECHANISMS UNDERLYING PHENOTYPIC REVERSION:
FUTURE PROSPECTS
Considering the wide variety of routes, which can lead to
reversion of the malignant phenotype, it is difficult to imagine
any single common mechanism underlying the phenomenon.
More likely multiple mechanisms are involved, and the
epigenetic correction of only one or at most a few of the
molecular errors in growth regulation specific to a particular
cancer may well be sufficient to trigger a normal program of
cell differentiation. The goal of future investigations will be to
pursue each available clue in expectation that the promise
inherent in tumor cell plasticity can and will be translated
into the clinical arena.
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